Q-omics provides the consensus-scored ZMAT4 profile across patient tissues and cancer cell-line models. ZMAT4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZMAT4 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZMAT4 RNA expression shows 12,119 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where ZMAT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMAT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMAT4 survival associations across molecular data types. ZMAT4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMAT4 RNA expression–survival associations across cancer types. High ZMAT4 expression shows unfavorable associations in ACC, LIHC, BLCA and CESC, but favorable associations in SKCM and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for ZMAT4 RNA expression.
This table summarizes ZMAT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZMAT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMAT4 shows lower tumor expression in THCA, COAD, STAD and KICH and higher tumor expression in KIRC and BRCA. The THCA box plot shows higher ZMAT4 RNA expression in normal versus tumor tissue (log2 FC = −5.026, t-test p < 0.001).
This table shows molecular features associated with ZMAT4 in patient tissues and cancer cell lines. In patient samples, ZMAT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMAT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
